

Aberrations of the MRE11â€“RAD50â€“NBS1 DNA damage
cancer: *MRE11* as a candidate familial cancerâ€“p

Molecular Oncology

2, 296-316

DOI: 10.1016/j.molonc.2008.09.007

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. <i>Molecular Oncology</i> , 2008, 2, 296-316. | 4.6 | 147 |
| 2 | Alternative Cyclin D1 Splice Forms Differentially Regulate the DNA Damage Response. <i>Cancer Research</i> , 2010, 70, 8802-8811. | 0.9 | 115 |
| 3 | Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 4517-4526. | 7.0 | 85 |
| 4 | Genetic susceptibility to breast cancer. <i>Molecular Oncology</i> , 2010, 4, 174-191. | 4.6 | 291 |
| 5 | Crystal Structure of the First Eubacterial Mre11 Nuclease Reveals Novel Features that May Discriminate Substrates During DNA Repair. <i>Journal of Molecular Biology</i> , 2010, 397, 647-663. | 4.2 | 41 |
| 6 | Discovering moderate-risk breast cancer susceptibility genes. <i>Current Opinion in Genetics and Development</i> , 2010, 20, 268-276. | 3.3 | 96 |
| 7 | DNA damage response, genetic instability and cancer: From mechanistic insights to personalized treatment. <i>Molecular Oncology</i> , 2011, 5, 303-307. | 4.6 | 28 |
| 8 | Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 205-214. | 27.0 | 754 |
| 9 | Constitutive expression of γ -H2AX has prognostic relevance in triple negative breast cancer. <i>Radiotherapy and Oncology</i> , 2011, 101, 39-45. | 0.6 | 74 |
| 10 | Genes Associated with Recurrence of Hepatocellular Carcinoma: Integrated Analysis by Gene Expression and Methylation Profiling. <i>Journal of Korean Medical Science</i> , 2011, 26, 1428. | 2.5 | 37 |
| 11 | Heterochromatin marks HP1 β , HP1 α and H3K9me3, and DNA damage response activation in human testis development and germ cell tumours. <i>Journal of Developmental and Physical Disabilities</i> , 2011, 34, e103-13. | 3.6 | 17 |
| 12 | Crystal Structure of Human Mre11: Understanding Tumorigenic Mutations. <i>Structure</i> , 2011, 19, 1591-1602. | 3.3 | 78 |
| 13 | Inherited Mutations in Breast Cancer Genes-Risk and Response. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2011, 16, 3-15. | 2.7 | 56 |
| 14 | Hodgkin lymphoma risk: Role of genetic polymorphisms and gene-gene interactions in DNA repair pathways. <i>Molecular Carcinogenesis</i> , 2011, 50, 825-834. | 2.7 | 29 |
| 15 | Crystal structure of the Mre11-Rad50-ATP13S complex: understanding the interplay between Mre11 and Rad50. <i>Genes and Development</i> , 2011, 25, 1091-1104. | 5.9 | 118 |
| 16 | The peculiarities of gene expression of medullary breast carcinoma tumor-associated antigens in different types of breast tumors. <i>Biopolymers and Cell</i> , 2012, 28, 381-388. | 0.4 | 1 |
| 17 | INT6/EIF3E Interacts with ATM and Is Required for Proper Execution of the DNA Damage Response in Human Cells. <i>Cancer Research</i> , 2012, 72, 2006-2016. | 0.9 | 18 |
| 18 | Role of MRE11 in Cell Proliferation, Tumor Invasion, and DNA Repair in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1485-1502. | 6.3 | 75 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Immunohistochemical analysis of medullary breast carcinoma autoantigens in different histological types of breast carcinomas. <i>Diagnostic Pathology</i> , 2012, 7, 161. | 2.0 | 14 |
| 20 | Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. <i>Cell Cycle</i> , 2012, 11, 3837-3850. | 2.6 | 144 |
| 21 | Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer. <i>Human Pathology</i> , 2012, 43, 1363-1375. | 2.0 | 2 |
| 22 | Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. <i>Radiotherapy and Oncology</i> , 2012, 105, 241-249. | 0.6 | 52 |
| 23 | Serological Analysis of SEREX-Defined Medullary Breast Carcinoma-Associated Antigens. <i>Cancer Investigation</i> , 2012, 30, 519-527. | 1.3 | 7 |
| 24 | RAD50 and NBS1 are not likely to be susceptibility genes in Chinese non-BRCA1/2 hereditary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 111-116. | 2.5 | 21 |
| 25 | Familial Breast Cancer Risk. <i>Current Breast Cancer Reports</i> , 2013, 5, 170-182. | 1.0 | 8 |
| 26 | Sodium tungstate modulates ATM function upon DNA damage. <i>FEBS Letters</i> , 2013, 587, 1579-1586. | 2.8 | 10 |
| 27 | The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation?. <i>Clinical Genetics</i> , 2013, 84, 407-414. | 2.0 | 19 |
| 28 | The MRN protein complex genes: MRE11 and RAD50 and susceptibility to head and neck cancers. <i>Molecular Cancer</i> , 2013, 12, 113. | 19.2 | 14 |
| 29 | Germline variants in MRE11/RAD50/NBN complex genes in childhood leukemia. <i>BMC Cancer</i> , 2013, 13, 457. | 2.6 | 10 |
| 30 | Hereditary breast cancer: ever more pieces to the polygenic puzzle. <i>Hereditary Cancer in Clinical Practice</i> , 2013, 11, 12. | 1.5 | 48 |
| 31 | Increased expression of phosphorylated NBS1, a key molecule of the DNA damage response machinery, is an adverse prognostic factor in patients with de novo myelodysplastic syndromes. <i>Leukemia Research</i> , 2013, 37, 1576-1582. | 0.8 | 13 |
| 32 | The Mre11 Complex Suppresses Oncogene-Driven Breast Tumorigenesis and Metastasis. <i>Molecular Cell</i> , 2013, 52, 353-365. | 9.7 | 46 |
| 33 | PC3 (BTG2/TIS21) possible role in chromosome instability syndromes. <i>Medical Hypotheses</i> , 2013, 81, 82-85. | 1.5 | 0 |
| 34 | Hereditary Breast Cancer: The Era of New Susceptibility Genes. <i>BioMed Research International</i> , 2013, 2013, 1-11. | 1.9 | 230 |
| 35 | Novel Integrative Genomics Approach for Associating GWAS Information with Intrinsic Subtypes of Breast Cancer. <i>Cancer Informatics</i> , 2013, 12, CIN.S11452. | 1.9 | 4 |
| 36 | Disease-associated MRE11 mutants impact ATM/ATR DNA damage signaling by distinct mechanisms. <i>Human Molecular Genetics</i> , 2013, 22, 5146-5159. | 2.9 | 44 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Regulation of the Nijmegen breakage syndrome 1 gene NBS1 by c-myc, p53 and coactivators mediates estrogen protection from DNA damage in breast cancer cells. International Journal of Oncology, 2013, 42, 712-720. | 3.3 | 13 |
| 38 | DNA Damage, DNA Repair and Cancer. , 0, , . | | 40 |
| 39 | XRCC3 and RAD51 Expression Are Associated with Clinical Factors in Breast Cancer. PLoS ONE, 2013, 8, e72104. | 2.5 | 19 |
| 40 | Suppression of Akt-mTOR Pathway-A Novel Component of Oncogene Induced DNA Damage Response Barrier in Breast Tumorigenesis. PLoS ONE, 2014, 9, e97076. | 2.5 | 12 |
| 41 | Growing recognition of the role for rare missense substitutions in breast cancer susceptibility. Biomarkers in Medicine, 2014, 8, 589-603. | 1.4 | 24 |
| 42 | RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy. Cancer Biology and Therapy, 2014, 15, 777-788. | 3.4 | 23 |
| 44 | Next-Generation Sequencing for Inherited Breast Cancer Risk: Counseling through the Complexity. Current Oncology Reports, 2014, 16, 371. | 4.0 | 52 |
| 45 | The cutting edges in DNA repair, licensing, and fidelity: DNA and RNA repair nucleases sculpt DNA to measure twice, cut once. DNA Repair, 2014, 19, 95-107. | 2.8 | 82 |
| 46 | Targeting DNA damage response in cancer therapy. Cancer Science, 2014, 105, 370-388. | 3.9 | 251 |
| 47 | Combined Genetic and Nutritional Risk Models of Triple Negative Breast Cancer. Nutrition and Cancer, 2014, 66, 955-963. | 2.0 | 32 |
| 48 | Expanding the genetic basis of copy number variation in familial breast cancer. Hereditary Cancer in Clinical Practice, 2014, 12, 15. | 1.5 | 15 |
| 49 | PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[1,4-b]indene Derivative in Lung Cancer Cells. Translational Oncology, 2014, 7, 256-266.e5. | 3.7 | 1 |
| 50 | Nucleases in homologous recombination as targets for cancer therapy. FEBS Letters, 2014, 588, 2446-2456. | 2.8 | 21 |
| 51 | Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. Breast Cancer Research, 2014, 16, R58. | 5.0 | 99 |
| 52 | 1053 Heterozygous germline mutations in MRE11 among Korean patients with high-risk breast cancer negative for BRCA1/2 mutation. European Journal of Cancer, 2015, 51, S162-S163. | 2.8 | 0 |
| 53 | Epigenetic Reduction of DNA Repair in Progression to Cancer. , 2015, , . | | 0 |
| 54 | Identification of Plasmodium falciparum DNA Repair Protein Mre11 with an Evolutionarily Conserved Nuclease Function. PLoS ONE, 2015, 10, e0125358. | 2.5 | 22 |
| 55 | Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment. Current Opinion in Obstetrics and Gynecology, 2015, 27, 23-33. | 2.0 | 33 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 56 | Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk. New England Journal of Medicine, 2015, 372, 2243-2257. | 27.0 | 764 |
| 57 | Multigene panel analysis identified germline mutations of <scp>DNA</scp> repair genes in breast and ovarian cancer. Molecular Genetics & Genomic Medicine, 2015, 3, 459-466. | 1.2 | 69 |
| 58 | Evaluation of miRNA-binding-site SNPs of MRE11A, NBS1, RAD51 and RAD52 involved in HRR pathway genes and risk of breast cancer in China. Molecular Genetics and Genomics, 2015, 290, 1141-1153. | 2.1 | 25 |
| 59 | Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress. Molecular Oncology, 2015, 9, 601-616. | 4.6 | 136 |
| 60 | Expression of the Mre11â€“Rad50â€“Nbs1 complex in cisplatin nephrotoxicity. Environmental Toxicology and Pharmacology, 2015, 40, 12-17. | 4.0 | 10 |
| 61 | RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families. SpringerPlus, 2015, 4, 92. | 1.2 | 21 |
| 62 | Heterozygous germline mutations in NBS1 among Korean patients with high-risk breast cancer negative for BRCA1/2 mutation. Familial Cancer, 2015, 14, 365-371. | 1.9 | 3 |
| 63 | ¹⁷⁷ Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine, 2015, 56, 501-502. | 5.0 | 5 |
| 64 | ATM and ATR as therapeutic targets in cancer. , 2015, 149, 124-138. | | 487 |
| 65 | Beyond BRCA: New hereditary breast cancer susceptibility genes. Cancer Treatment Reviews, 2015, 41, 1-8. | 7.7 | 166 |
| 66 | Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 44-56. | 3.8 | 19 |
| 67 | Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players. Frontiers in Oncology, 2016, 6, 45. | 2.8 | 17 |
| 68 | Hereditary breast and ovarian cancer: new genes in confined pathways. Nature Reviews Cancer, 2016, 16, 599-612. | 28.4 | 305 |
| 69 | Means to the ends: The role of telomeres and telomere processing machinery in metastasis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 320-329. | 7.4 | 17 |
| 70 | Impact of race and tumor subtype on second malignancy risk in women with breast cancer. SpringerPlus, 2016, 5, 14. | 1.2 | 13 |
| 71 | Programmed <scp>DNA</scp> breaks in lymphoid cells: repair mechanisms and consequences in human disease. Immunology, 2016, 147, 11-20. | 4.4 | 11 |
| 72 | Role of Runx2 in breast cancer-mediated bone metastasis. International Journal of Biological Macromolecules, 2017, 99, 608-614. | 7.5 | 49 |
| 73 | MRE11 stability is regulated by CK2-dependent interaction with R2TP complex. Oncogene, 2017, 36, 4943-4950. | 5.9 | 38 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 74 | The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition. Current Treatment Options in Oncology, 2017, 18, 27. | 3.0 | 25 |
| 75 | Next-Generation Sequencing Reveals a Nonsense Mutation (p.Arg364Ter) in MRE11A Gene in an Indian Patient with Familial Breast Cancer. Breast Care, 2017, 12, 112-114. | 1.4 | 3 |
| 76 | PLGA-CTAB curcumin nanoparticles: Fabrication, characterization and molecular basis of anticancer activity in triple negative breast cancer cell lines (MDA-MB-231 cells). Biomedicine and Pharmacotherapy, 2017, 94, 944-954. | 5.6 | 36 |
| 77 | MRE11 Promotes Tumorigenesis by Facilitating Resistance to Oncogene-Induced Replication Stress. Cancer Research, 2017, 77, 5327-5338. | 0.9 | 22 |
| 78 | Association of DNA repair genes polymorphisms and mutations with increased risk of head and neck cancer: a review. Medical Oncology, 2017, 34, 197. | 2.5 | 46 |
| 79 | Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer. BMC Cancer, 2017, 17, 44. | 2.6 | 36 |
| 80 | Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer. Breast Cancer Research and Treatment, 2017, 161, 95-102. | 2.5 | 28 |
| 81 | Panel of SEREX-defined antigens for breast cancer autoantibodies profile detection. Biomarkers, 2017, 22, 149-156. | 1.9 | 15 |
| 82 | Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. Annals of Oncology, 2017, 28, 44-56. | 1.2 | 43 |
| 83 | Outcomes of retesting BRCA negative patients using multigene panels. Familial Cancer, 2017, 16, 319-328. | 1.9 | 18 |
| 84 | Exome Sequencing in a Family with Luminal-Type Breast Cancer Underpinned by Variation in the Methylation Pathway. International Journal of Molecular Sciences, 2017, 18, 467. | 4.1 | 14 |
| 85 | Early Postoperative Low Expression of RAD50 in Rectal Cancer Patients Associates with Disease-Free Survival. Cancers, 2017, 9, 163. | 3.7 | 12 |
| 86 | Targeting ATR for Cancer Therapy: Profile and Expectations for ATR Inhibitors. Cancer Drug Discovery and Development, 2018, , 63-97. | 0.4 | 0 |
| 87 | Reversible mislocalization of a disease-associated MRE11 splice variant product. Scientific Reports, 2018, 8, 10121. | 3.3 | 3 |
| 88 | Revisiting Non-BRCA1/2 Familial Whole Exome Sequencing Datasets Implicates NCK1 as a Cancer Gene. Frontiers in Genetics, 2019, 10, 527. | 2.3 | 4 |
| 89 | Attenuating the DNA damage response to double-strand breaks restores function in models of CNS neurodegeneration. Brain Communications, 2019, 1, fcz005. | 3.3 | 20 |
| 90 | RAD6B Plays a Critical Role in Neuronal DNA Damage Response to Resist Neurodegeneration. Frontiers in Cellular Neuroscience, 2019, 13, 392. | 3.7 | 14 |
| 91 | Prognostic effects of abnormal DNA damage response protein expression in breast cancer. Breast Cancer Research and Treatment, 2019, 175, 117-127. | 2.5 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 92 | RECQL5 plays an essential role in maintaining genome stability and viability of triple-negative breast cancer cells. <i>Cancer Medicine</i> , 2019, 8, 4743-4752. | 2.8 | 14 |
| 93 | Association between polymorphisms in MRE11 and HIV-1 susceptibility and AIDS progression in a northern Chinese MSM population. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2009-2018. | 3.0 | 1 |
| 94 | Expression of γ -H2AX and patient prognosis in breast cancer cohort. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 12958-12965. | 2.6 | 6 |
| 95 | Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. <i>Journal of Hematology and Oncology</i> , 2019, 12, 38. | 17.0 | 66 |
| 96 | Harnessing DNA Double-Strand Break Repair for Cancer Treatment. <i>Frontiers in Oncology</i> , 2019, 9, 1388. | 2.8 | 143 |
| 97 | Updates in the field of hereditary nonpolyposis colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 707-720. | 3.0 | 18 |
| 98 | A Survey of Reported Disease-Related Mutations in the MRE11-RAD50-NBS1 Complex. <i>Cells</i> , 2020, 9, 1678. | 4.1 | 18 |
| 99 | An assessment of poly (ADP-ribose) polymerase-1 role in normal and cancer cells. <i>BioFactors</i> , 2020, 46, 894-905. | 5.4 | 19 |
| 100 | A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability. <i>Cell Reports</i> , 2020, 30, 1385-1399.e7. | 6.4 | 29 |
| 101 | Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1128. | 4.1 | 61 |
| 102 | DNA damage response and breast cancer development: Possible therapeutic applications of ATR, ATM, PARP, BRCA1 inhibition. <i>DNA Repair</i> , 2021, 98, 103032. | 2.8 | 13 |
| 104 | Germline risk of clonal haematopoiesis. <i>Nature Reviews Genetics</i> , 2021, 22, 603-617. | 16.3 | 48 |
| 105 | Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications. <i>Oncologist</i> , 2021, 26, e1526-e1537. | 3.7 | 53 |
| 107 | The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families. <i>Cancers</i> , 2021, 13, 3406. | 3.7 | 9 |
| 108 | MRN Complex and Cancer Risk: Old Bottles, New Wine. <i>Clinical Cancer Research</i> , 2021, 27, 5465-5471. | 7.0 | 6 |
| 109 | MRE11 as a molecular signature and therapeutic target for cancer treatment with radiotherapy. <i>Cancer Letters</i> , 2021, 514, 1-11. | 7.2 | 15 |
| 110 | Understanding the DNA double-strand break repair and its therapeutic implications. <i>DNA Repair</i> , 2021, 106, 103177. | 2.8 | 13 |
| 111 | Circadian-disruption-induced gene expression changes in rodent mammary tissues. <i>Oncoscience</i> , 2016, 3, 58-70. | 2.2 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 112 | Double-strand break repair and colorectal cancer: gene variants within 3' UTRs and microRNAs binding as modulators of cancer risk and clinical outcome. <i>Oncotarget</i> , 2016, 7, 23156-23169. | 1.8 | 40 |
| 113 | Molecular Genetics of Breast and Ovarian Cancer: Recent Advances and Clinical Implications. <i>Balkan Journal of Medical Genetics</i> , 2012, 15, 75-80. | 0.5 | 2 |
| 114 | Loss of BRCA1 expression leads to worse survival in patients with gastric carcinoma. <i>World Journal of Gastroenterology</i> , 2013, 19, 1968. | 3.3 | 23 |
| 115 | Development and validation of a 36-gene sequencing assay for hereditary cancer risk assessment. <i>PeerJ</i> , 2017, 5, e3046. | 2.0 | 18 |
| 116 | Suppression of isoprenylcysteine carboxylmethyltransferase compromises DNA damage repair. <i>Life Science Alliance</i> , 2021, 4, e202101144. | 2.8 | 1 |
| 117 | TYPES OF DNA DAMAGE. , 2013, , 115-118. | | 0 |
| 118 | Breast Cancer Genetics and Risk Assessment. , 2015, , 1-21. | | 0 |
| 119 | Next-Generation Sequencing Based Testing for Breast Cancer. , 2016, , 299-328. | | 0 |
| 122 | Hereditary : BRCA and Other. , 2020, , 23-41. | | 0 |
| 123 | Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 7059-71. | 0.5 | 10 |
| 124 | DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition. <i>American Journal of Cancer Research</i> , 2015, 5, 2113-26. | 1.4 | 20 |
| 125 | The deubiquitinase USP28 stabilizes the expression of RecQ family helicases and maintains the viability of triple negative breast cancer cells. <i>Journal of Biological Chemistry</i> , 2022, 298, 101443. | 3.4 | 6 |
| 126 | Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers. <i>Npj Breast Cancer</i> , 2021, 7, 143. | 5.2 | 8 |
| 127 | An <i>in-silico</i> analysis to identify structural, functional and regulatory role of SNPs in <i>hMRE11</i> . <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 2160-2174. | 3.5 | 2 |
| 128 | Germline Mutation Analysis in Sporadic Breast Cancer Cases With Clinical Correlations. <i>Frontiers in Genetics</i> , 2022, 13, 820610. | 2.3 | 0 |
| 129 | ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy. <i>Journal of the ICRU</i> , 2021, 21, 1-212. | 15.5 | 52 |
| 138 | Exome sequencing reveals a distinct somatic genomic landscape in breast cancer from women with germline PTEN variants. <i>American Journal of Human Genetics</i> , 2022, 109, 1520-1533. | 6.2 | 2 |
| 139 | Integrative Expression, Survival Analysis and Cellular miR-2909 Molecular Interplay in MRN Complex Check Point Sensor Genes (MRN-CSG) Involved in Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, e850-e862. | 2.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 140 | Crosstalk between SUMOylation and ubiquitylation controls DNA end resection by maintaining MRE11 homeostasis on chromatin. Nature Communications, 2022, 13, . | 12.8 | 3 |
| 141 | Molecular targets that sensitize cancer to radiation killing: From the bench to the bedside. Biomedicine and Pharmacotherapy, 2023, 158, 114126. | 5.6 | 1 |
| 142 | Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γ H2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases. BMC Cancer, 2022, 22, . | 2.6 | 1 |
| 143 | Importance of Germline and Somatic Alterations in Human MRE11, RAD50, and NBN Genes Coding for MRN Complex. International Journal of Molecular Sciences, 2023, 24, 5612. | 4.1 | 5 |
| 145 | Integrating somatic CNV and gene expression in breast cancers from women with PTEN hamartoma tumor syndrome. Npj Genomic Medicine, 2023, 8, . | 3.8 | 0 |
| 146 | Interactions between the DNA Damage Response and the Telomere Complex in Carcinogenesis: A Hypothesis. Current Issues in Molecular Biology, 2023, 45, 7582-7616. | 2.4 | 0 |
| 147 | Chromosome 5. , 2023, , 90-158. | | 0 |